Sanofi Looks To Climb Consumer Ladder In Boehringer Business Swap
This article was originally published in The Tan Sheet
Executive Summary
A pending agreement includes a $5.2bn cash payment from Boehringer to Sanofi but excludes Boehringer’s consumer product business in China. The brands Sanofi will add to its consumer health lineup include two marketed in the US, Dulcolax constipation relief and Zantac heartburn remedy.
You may also be interested in...
Deal Watch: Merck Hopes Moderna's Personalized Vaccines Can Increase Keytruda Patient Base
Novartis and Xencor sign wide-ranging immuno-oncology collaboration targeting multiple CD pathways. Teva signs divestment agreements with five firms during June to meet FTC requirements for its acquisition of Allergan's generics business.
Sanofi Adds Consumer Brands, Grows Footprint With Boehringer Ingelheim Deal
BI international brands including Mucoangin cough suppressant and Dulcolax constipation treatment and US heartburn remedy Zantac would join Sanofi's consumer portfolio including US brands Allegra Allergy antihistamines and Nasacort Allergy 24HR nasal decongestant in the firm's proposed asset swap.
Sanofi Adds Consumer Brands, Grows Footprint With Boehringer Ingelheim Deal
BI international brands including Mucoangin cough suppressant and Dulcolax constipation treatment and US heartburn remedy Zantac would join Sanofi's consumer portfolio including US brands Allegra Allergy antihistamines and Nasacort Allergy 24HR nasal decongestant in the firm's proposed asset swap.